HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.09
-0.25 (-1.63%)
At close: Jun 27, 2025, 4:00 PM
15.10
+0.01 (0.07%)
After-hours: Jun 27, 2025, 4:04 PM EDT
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue (ttm)
$630.20M
Revenue Growth
-24.80%
P/S Ratio
4.40
Revenue / Employee
$347,985
Employees
1,811
Market Cap
2.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HCM News
- 23 days ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 26 days ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 5 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 3 months ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 3 months ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 3 months ago - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewsWire